SCHEMBL10050491

SCHEMBL10050491

Cc1ccc(S(=O)(=O)OC(=O)Cc2ccn(S(=O)(=O)c3ccc(C)cc3)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
GRM4 Q14833 1/20 0.41
HTR6 P50406 1/20 0.40
ALDH1A1 P00352 4/20 0.39
PKM P14618 2/20 0.38
GAA P10253 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC3 O15379 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7781061 0.87 CA1 (0.46) CA1CA2GRM4HTR6ALDH1A1
SCHEMBL7775878 0.82 CA1 (0.50) CA1CA2GRM4HTR6ALDH1A1
SCHEMBL4513275 0.79 CA1 (0.49) CA1CA2GRM4HTR6ALDH1A1
SCHEMBL4521506 0.78 CA1 (0.54) CA1CA2GRM4HTR6ALDH1A1
SCHEMBL310996 0.76 CA1 (0.46) CA1CA2GRM4HTR6ALDH1A1
SCHEMBL18920634 0.76 ALDH1A1 (0.47) CA1CA2GRM4HTR6ALDH1A1
SCHEMBL18920633 0.76 CA1 (0.43) CA1CA2GRM4HTR6ALDH1A1
SCHEMBL4227579 0.75 HTR6 (0.52) CA1CA2GRM4HTR6ALDH1A1
SCHEMBL21806794 0.75 CA1 (0.54) CA1CA2GRM4HTR6ALDH1A1
SCHEMBL5034041 0.75 HTR6 (0.56) HTR6PKMKMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8092661-B2 Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin BIOMERIEUX (FR) 2012-01-10 US disclosed
US-8092661-B2 Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin BIOMERIEUX (FR) 2012-01-10 US disclosed
US-20090314660-A1 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin BIOMERIEUX (FR) 2009-12-24 US disclosed
US-20090314660-A1 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin BIOMERIEUX (FR) 2009-12-24 US disclosed
WO-2007051947-A1 NOVEL ELECTROPOLYMERISABLE MONOMERS WHICH ARE SOLUBLE IN AN AQUEOUS SOLUTION AND COMPRISE A METALLOPORPHYRINE BIOMERIEUX (FR) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090314660-A1 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin EPS15, PPOX, ACR CA1 935/4885CA2 1270/4885GRM4 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.